35216-39-8|3-(Methylsulfonyl)aniline| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 35216-39-8 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 35216-39-8 ]

CAS No. :	35216-39-8
Formula :	C₇H₉NO₂S
M.W :	171.22
SMILES Code :	NC1=CC=CC(S(=O)(C)=O)=C1
MDL No. :	MFCD03764428
InChI Key :	MBNPJRQKQLLRIS-UHFFFAOYSA-N
Pubchem ID :	428029

Safety of [ 35216-39-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 35216-39-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.14
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	43.94
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	68.54 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.9
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.29
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.76
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	0.9
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.4
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	0.85

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.42
Solubility	6.48 mg/ml ; 0.0379 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.29
Solubility	8.75 mg/ml ; 0.0511 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.35
Solubility	0.774 mg/ml ; 0.00452 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-7.14 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.8

Application In Synthesis of [ 35216-39-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 35216-39-8 ]

[ 35216-39-8 ] Synthesis Path-Downstream 1~35

1
[ 33951-33-6 ]
[ 35216-39-8 ]

References: [1]Iowa State College Journal of Science,1946,vol. 21,p. 38.

2
[ 2976-32-1 ]
[ 35216-39-8 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogen;palladium 10% on activated carbon; In methanol; for 2.333h;Inert atmosphere;	2.0 g (0.0098 mol) of 4 was dissolved in 100 mL of methanol, and an aqueous suspension of Pd/C (10 %) was added under Ar atmosphere. The reaction mixture was additionally purged under Ar for 20 min. At this time, the reaction mixture was hydrogenated until the reduction was compiete. The reaction was stirred for 2 h. The precipitate was carefully filtered and the residue was collected under reduced pressure. Compound 5 was crystallized from ether and dried on air. The crude yield was 89 % (1.5 g).

References: [1]Journal of Medicinal Chemistry,1990,vol. 33,p. 1360 - 1363.
[2]Recueil des Travaux Chimiques des Pays-Bas,1954,vol. 73,p. 819,829.
[3]Journal of the Chemical Society,1938,p. 899,902.
[4]Journal of the Chemical Society,1945,p. 633,639.
[5]Journal of Medicinal Chemistry,1990,vol. 33,p. 112 - 121.
[6]Helvetica Chimica Acta,1981,vol. 64,p. 1849 - 1853.
[7]Patent: WO2010/118367,2010,A2 .Location in patent: Page/Page column 89.

3
[ 35216-39-8 ]
[ 14763-61-2 ]

References: [1]Journal of the Chemical Society,1938,p. 899,902.

4
[ 35216-39-8 ]
[ 22821-75-6 ]

References: [1]Journal of the Chemical Society,1945,p. 633,639.

5
[ 35216-39-8 ]
[ 108-24-7 ]
[ 58202-85-0 ]

References: [1]Recueil des Travaux Chimiques des Pays-Bas,1954,vol. 73,p. 819,829.

6
[ 35216-39-8 ]
[ 586-96-9 ]
[ 107516-85-8 ]

References: [1]Annali di Chimica,1956,vol. 46,p. 199,207.

7
[ 35216-39-8 ]
[ 121-60-8 ]
sulfanilic acid-(3-methanesulfonyl-anilide) [ No CAS ]

References: [1]Patent: DE755395,1939, .
DRP/DRBP Org.Chem.,.

8
[ 75-21-8 ]
[ 35216-39-8 ]
2-[(2-Hydroxy-ethyl)-(3-methanesulfonyl-phenyl)-amino]-ethanol [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1990,vol. 33,p. 112 - 121.

9
[ 35216-39-8 ]
[ 124-63-0 ]
N-(3-Methanesulfonyl-phenyl)-methanesulfonamide [ No CAS ]

References: [1]Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy,1982,vol. 38,p. 791 - 796.

10
[ 35216-39-8 ]
[ 79064-26-9 ]
[ 125802-65-5 ]

References: [1]Journal of Medicinal Chemistry,1990,vol. 33,p. 1360 - 1363.

11
[ 35216-39-8 ]
[ 116332-55-9 ]
2-(4-fluorophenyl)-1-[3-(methylsulfonyl)phenyl]-1H-pyrrole [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1997,vol. 40,p. 1619 - 1633.

12
[ 35216-39-8 ]
[ 15268-31-2 ]
1-(3-methanesulfonyl-phenyl)-3-pyridin-3-yl-urea [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,1999,vol. 7,p. 2767 - 2773.

Yield	Reaction Conditions	Operation in experiment
92%	With potassium phosphate; copper(l) iodide; C16H18N2O2; In dimethyl sulfoxide; at 90℃; for 24h;Schlenk technique; Inert atmosphere;	General procedure: Sodium alkylsulfinate or sodium arylsulfinate (6.5 mmol), copper iodide (of which the dosage was shown in the following table), ligand (of which the dosage was shown in the following table) and potassium phosphate (5.0 mmol) were added into a 10 mL Schlenk tube. The tube was evacuated and filled with argon for three times, and then aryl chloride (5 mmol) and 4 mL of DMSO were added. The reaction mixture was homogeneously stirred at corresponding temperature for 24 hours. After cooling, the contents of the of Schlenk tube were washed with ethyl acetate, and filtered through silica gel and diatomite plug. The filtrate was concentrated and purified by column chromatography to give the corresponding product.
		Step 2 Preparation of (3-amino)phenyl methyl sulphone (3-Nitro)phenyl methyl sulphone (prepared as described in Step 1 above) (5.396 g) reduced iron (7.5 g) and ammonium chloride (7.18 g) were mixed together in ethanol/water (2:1) (150 ml) and heated under reflux for 2 hours. The black solution was filtered through `Celite` and the pad washed with ethyl acetate. The solvents were removed under reduced pressure and the residue taken up in ethyl acetate/water. The organic layer was separated and the aqueous layer extracted with 3 further portions of ethyl acetate. The combined organic layers were washed with brine and the solvent removed under reduced pressure to give a dark orange oil (3.9275 g). This was chromatographed on silica gel using ethyl acetate-hexane (45:55 to 50:50) as eluant to give the title compound as an orange oil, yield 3.607 g. 1 H nmr (CDCl3): delta3.02 (3H, s), 3.8-4.2 (2H, broad s), 6.90 (1H, m), 7.18-7.38 (3H, m)
	With palladium 10% on activated carbon; hydrogen; In methanol; at 20℃; for 16h;	General procedure: A solution of 1 -ethyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine (step 2 intermediate)(800 mg, 2.52 mmol) in methanol (20 mL) with catalytic amount of 10% palladium oncarbon (50% wet) was hydrogenated at RT for 16 h. The mixture was filtered through celite and the celite bed was rinsed with methanol. The combined filtrate and washings were concentrated and the residue thus obtained was purified by silica gel column chromatography to yield 600 mg of the desired product. ?H NMR (400 MHz, DMSO-d6) oe 0.97 (t, J = 7.2 Hz,3H), 2.26-2.51 (m, 1OH), 3.38 (s, 2H), 5.44 (s, 2H), 6.74 (dd, J, = 2.4 Hz, J2 = 8.4 Hz, 1H),6.85 (s, 1H), 7.29 (t, J 8.4 Hz, 1H).

15
[ 33951-33-6 ]
[ 7664-41-7 ]
sodium amide [ No CAS ]
[ 35216-39-8 ]

References: [1]Iowa State College Journal of Science,1946,vol. 21,p. 38.

16
[ 35216-39-8 ]
3-m-tolyl-2-trifluoromethanesulfonyloxy-propionic acid ethyl ester [ No CAS ]
2-(3-methanesulfonyl-phenylamino)-3-m-tolyl-propionic acid ethyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 4121 - 4124.

17
[ 1783-81-9 ]
[ 35216-39-8 ]

Yield	Reaction Conditions	Operation in experiment
92%	With sodium tungstate; dihydrogen peroxide; acetic acid; In water; at 65℃; for 1.5h;	General procedure: A mixture of Na2W04 (0.067 g), 1 drop of acetic acid, and H20 (5 mL) was placed in a flask and heated to 65 C. Methylthioaniline 153, 154, or 161 (500 mg, 3.59 mmol) was added, followed by dropwise addition of H202 (1.1 mL, 10.77 mmol). The mixture was stirred at 65 C for 1.5 h and, after cooling, 80 mL of 1 N HC1 and 50 mL of DCM were added. The layers were separated, and the aqueous phase was washed with additional DCM. The aqueous phase was basified with 25% NaOH and extracted with DCM. The organic phase was washed with brine and dried over Na2S04. The solvent was removed to give methylsulfonyl aniline derivatives 157, 158 and 164. [0232] 3-(methylsulfonyl)aniline (158). Compound 158 was prepared according to procedure E from 153 to afford 557 mg of brown powder (92%). 1H NMR (500 MHz, CDC13) delta 3.03 (s, 3H), 6.89 (ddd, J = 0.8, 2.3, 8.0 Hz, 1H), 7.21 (t, J = 2.1Hz, 1H), 7.24 (dt, J = 1.1, 7.7Hz, 1H), 7.30 (t, 7.8Hz, 1H). 13C NMR (126 MHz, CDC13) delta 44.40, 112.69, 116.37, 119.72, 130.30, 141.16, 147.69. LCQ (M+H+) calcd C7H9N02S 172, found 172.
14%	With 3-chloro-benzenecarboperoxoic acid; In chloroform; at 0℃; for 1.5h;	150 mg (1.22 mmol, 1 eq.) of (3-methylmercapto)aniline are dissolved in 3 mL of chloroform. 420 mg (2.43 mmol, 2 eq.) of meta-chloroperbenzoic acid are added to this solution. The mixture is stirred for 1 hour 30 min. at 0 C. A saturated NaHCO3 solution is added and the aqueous phase is extracted with DCM. The organic phase is washed with brine, dried over MgSO4, filtered and concentrated. The residue is purified by chromatography over silica gel (eluent: DCM/ AcOEt 8/1 to 6/1) to give 30 mg of product (yield = 14 %).]U NMR(400 MHz, CDCl3): ppm 3.02 (s, 3H, CH3), 3.73-4.22 (m, 2H, NH2), 6.89 (d, IH, aromatic H), 7.18-7.23 (m, 3H, aromatic H) MS: 172.09+ (M+H)+, 213.13+ (M+H+CH3CN)+

References: [1]Patent: WO2014/100833,2014,A1 .Location in patent: Paragraph 0080; 0232.
[2]Patent: WO2007/60026,2007,A1 .Location in patent: Page/Page column 49-50.
[3]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4741 - 4745.

18
[ 35216-39-8 ]
[ 312303-93-8 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; stannous chloride; hydrazine hydrochloride; sodium nitrite; In hydrogenchloride; water;	Step 2 Preparation of (3-methanesulfonyl-phenyl)-hydrazine To a solution of <strong>[35216-39-8]3-methanesulphonyl-phenylamine</strong> (2.5 g) in 6 mL HCl was added a solution of NaNO2 in 5 mL of H2O at -5 to 0 C. After stirring for 30 min the resulted diazonium salt was poured into a cold solution (-10 to -15 C.) of stannous chloride in 6 ml HCl. The mixture of resulted hydrazine hydrochloride in HCl was stored in the refrigerator overnight. The solution was basified to pH 10, by addition of a 6N solution of NaOH, and extracted with THF. The organic layer was washed, dried over MgSO4, and evaporated to yield 2 g of a light brown solid (3-methanesulfonyl-phenyl)-hydrazine.

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4741 - 4745.
[2]Patent: US2003/130337,2003,A1 .

19
[ 851916-81-9 ]
[ 35216-39-8 ]
(2,6-dichloro-phenyl)-[2-(3-methanesulfonyl-phenylamino)-imidazo[1,2-a]pyridin-6-yl]-methanone [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 1943 - 1947.

20
(5-bromo-2-imino-2H-pyridin-1-yl)-acetic acid methyl ester; hydrobromide [ No CAS ]
[ 35216-39-8 ]
[ 83-38-5 ]
(2,6-dichloro-phenyl)-[2-(3-methanesulfonyl-phenylamino)-imidazo[1,2-a]pyridin-6-yl]-methanone [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2005,vol. 15,p. 1943 - 1947.

21
[ 861136-83-6 ]
[ 35216-39-8 ]
[ 861136-92-7 ]

References: [1]Synthesis,2005,p. 1550 - 1554.

22
[ 861136-84-7 ]
[ 35216-39-8 ]
[ 861136-87-0 ]

References: [1]Synthesis,2005,p. 1550 - 1554.

23
[ 35216-39-8 ]
[ 82353-55-7 ]
[(S)-2-(3-Methanesulfonyl-phenylamino)-1-methyl-ethyl]-carbamic acid benzyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1975 - 1980.

24
[ 463-71-8 ]
[ 35216-39-8 ]
[ 54743-68-9 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 28 - 33.

25
[ 80151-37-7 ]
[ 35216-39-8 ]
2-(2-benzyloxy-phenyl)-1-(3-methanesulfonyl-phenyl)-5-methyl-1H-pyrrole [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 1200 - 1205.

26
[ 632625-42-4 ]
[ 35216-39-8 ]
3-{2-[5-chloro-2-(benzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-methanesulfonyl benzene [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 1200 - 1205.

27
[ 632625-44-6 ]
[ 35216-39-8 ]
2-(2-benzyloxy-5-bromo-phenyl)-1-(3-methanesulfonyl-phenyl)-5-methyl-1H-pyrrole [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 1200 - 1205.

28
[ 94-75-7 ]
[ 35216-39-8 ]
2-(2,4-dichlorophenoxy)-N-(3-methanesulfonylphenyl)acetamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55.02%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide;	<Example 40> 2-(2,4-dichloro-phenoxy)-N-(3-methanesulfonyl-phenyl)-acetamide <n="43"/>To 2,4-dichlophihenoxyacetic acid (110.6 mg, 0.5 mmol), 3-methylsulphonylaniline (128.4 mg, 0.75 mmol), N<3-dimethylaminopropyl>N'-ethyl carbodiimideHCl (EDC). (143.8 mg, 0.75 mmol) and 1- hydroxybenzotriazole (HOBt) (102.1 mg, 0.75 mmol) in DMF (5mL) was added N, N-diisopropylethyamine, redistilled (DIPEA) (0.13 ml, 0.75 mmol). The mixture was stirred overnight, and then partitioned between ethyl acetate and 10% HCl. The organic phase was washed with brine, dried (MgSCvt anh), and concentrated. The residue was purified by silica gel flash column chromatography (CH2CH2MeOH = 15:1) to give 2-(2,4-dichloro- phenoxy)-N-(3-memanesutfonyl-phenyl)-acetamide as a white solid (103.0 mg, 55.02% yield).IH-NMR (CD3OD and DMSO-d6, 300 Hz) 8.41 (IH, m, aromatic-H), 7.99 - 8.03 (IH5 m, aromatic- H), 7.66 - 7.79 (3H5 m, aromatic-H), 7.45 (IH, dd, J = 9.0 & 2.4 Hz, aromatic-H), 7.24 (IH5 d, J = 9.0 Hz5 aromatic-H), 4.30 (ZH, s, CH2), 3.27 (3H5 s, CH3).
55.02%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide;	To 2,4-dichlorophenoxyacetic acid (110.6 mg, 0.5 mmol), 3-methylsulphonylaniline (128.4 mg, 0.75 mmol), N-(3-dimethylaminopropyl)-N'-ethyl carbodiimide HCl (EDC) (143.8 mg, 0.75 mmol) and 1-hydroxybenzotriazole (HOBt) (102.1 mg, 0.75 mmol) in DMF (5 mL) was added N,N-diisopropylethylamine, redistilled (DIPEA) (0.13 ml, 0.75 mmol). The mixture was stirred overnight, and then partitioned between ethyl acetate and 10% HCl. The organic phase was washed with brine, dried (MgSO4 anh), and concentrated. The residue was purified by silica gel flash column chromatography (CH2CH2:MeOH=15:1) to give 2-(2,4-dichloro-phenoxy)-N-3-methanesulfonyl-phenyl)-acetamide as a white solid (103.0 mg, 55.02% yield). 1H-NMR (CD3OD and DMSO-d6, 300 Hz) 8.41 (1H, m, aromatic-H), 7.99-8.03 (1H, m, aromatic-H), 7.66-7.79 (3H, m, aromatic-H), 7.45 (1H, dd, J=9.0 & 2.4 Hz, aromatic-H), 7.24 (1H, d, J=9.0 Hz, aromatic-H), 4.30 (2H, s, CH2), 3.27 (3H, s, CH3).

References: [1]Patent: WO2008/4798,2008,A1 .Location in patent: Page/Page column 40; 41.
[2]Bulletin of the Korean Chemical Society,2011,vol. 32,p. 3666 - 3674.
[3]Patent: US2009/306078,2009,A1 .Location in patent: Page/Page column 32.

29
[ 35216-39-8 ]
2-cyano-2-(3-methanesulfonyl-phenylthiocarbamoyl)-acetamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 28 - 33.

30
[ 35216-39-8 ]
3-hydroxy-5-(3-methanesulfonyl-phenylamino)-isothiazole-4-carbonitrile [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 28 - 33.

31
[ 35216-39-8 ]
N-(3-methanesulfonyl-phenyl)-N'-[2-(4-methoxy-phenoxy)-1-methyl-ethylidene]-hydrazine [ No CAS ]